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Trachoma is the leading infectious cause 
of blindness and is endemic in 53 countries. 
An estimated 325 million people live in 
areas where they can be exposed to 
trachoma, and more than 7 million suffer 
from trichiasis, the final painful stage of 
this eye disease.
The World Health Organization (WHO) 
initiated a global programme to eliminate 
trachoma by 2020. At its core is the SAFE 
strategy: Surgery, Antibiotics, Facial 
cleanliness and Environmental 
improvement to reduce transmission. 
Trachoma control efforts have increased 
with mass drug administration (MDA) of 
azithromycin (Zithromax), an antibiotic 
donated by Pfi zer Inc. The goal is 80% 
coverage in endemic areas for at least 
3 years. 
To maximise coverage, programme 
managers and health workers must 
understand the community’s knowledge 
and health priorities as well as their 
attitudes and beliefs. 
This has been well demonstrated in 
other successful public health 
programmes in Africa, e.g. the Africa 
Program for Onchocerciasis Control (APOC)1 
and the Guinea Worm Program (GWP).2 
This article distils what has been 
learned from MDA programmes in Kenya, 
where trachoma control activities have 
been initiated in eight districts. 
Successful MDA programmes depend 
on completing all of the following activities 
in each district where MDA will take place.
1. Planning 
Health workers in managerial positions, 
also referred to as the District Health 
Management Team (DHMT), gather to do 
the following:
• choose drug distribution points and drug 
storage sites
• determine the target population for each 
location and distribution point
• procure the drugs (azithromycin)
• determine the human resources needed
• select divisional coordinators and 
supervisors
• prepare the distribution budget
• meet with the partner(s) supporting 
MDA, which may be an NGO and/or a 
district or regional authority.
2. sensitisation of 
stakeholders and mobilisation 
of the community
The DHMTs are responsible for creating 
awareness about MDA. This is aimed at 
everyone involved in – and affected by – 
the MDA programme. 
In each division (a population of around 
50,000 people) the DHMT organises 
workshops with local chiefs and assistant 
chiefs and ask them to encourage their 
communities to get involved. The staff 
member designated as the divisional 
coordinator explains the purpose of the 
MDA, the reasons for choosing this area, 
and the drugs being used. They also 
discuss the potential side effects of the 
drugs to dispel negative information and 
perceptions. 
We have found that it is best to engage 
everyone in discussion, rather than merely 
giving a lecture. This gives community 
members a chance to express any fears or 
concerns they may have. 
If there are several ethnic groups in the 
target area these may need different 
approaches in order that they understand 
and participate in distribution. Protecting 
the future generation from disease is a 
message that resonates well in most 
communities. 
Speaking to faith-based organisations 
about MDA, and engaging the local media 
and opinion leaders, are also important in 
getting a community ready to actively 
support distribution and to accept the 
drugs. This is also known as community 
mobilisation. Community Health 
Extension Workers (CHEWs) in the area 
will assist by educating the community 
about the importance of hygiene and 
sanitation.
3. recruitment of volunteers 
and community mapping
First, the DHMT members involved in 
managing the MDA meet to discuss the 
number of CHEWs and community volun-
teers needed (Table 1) and what training 
they might require. Chiefs, assistant chiefs, 
and local opinion leaders help to choose the 
community volunteers. In communities 
where there are already trained community 
health workers, the community volunteers 
will be chosen from among them. 
Community mapping involves assessing 
the population in an area and identifying 
public facilities such as schools, clinics and 
churches that can be used as distribution 
points. Distribution dates are determined, 
based on places or activities that bring 
people together, such as market days. 
Mass treatment for trachoma: 
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District Health Management team (DHMt). The team of health managers and 
leaders who oversee mass drug administration in a district (population of 300,000 
to 600,000). Divisional coordinators and some supervisors are also members.
Divisional coordinator. Responsible for training of community volunteers and 
CHEWs and for community mobilisation in the division (population of around 
50,000 people). Oversees the activities of 8–10 supervisors during MDA.
Supervisor. Oversees 6–10 distribution teams in one location (population of 
around 10,000 people). Liaises with chiefs and assistant chiefs and helps to ensure 
logistical support is available to teams. Reports to divisional coordinator.
Community Health Extension Workers (CHEWs). They are trained nurses and/or 
public health officers or technicians who work at the health facilities (dispensaries 
and health centers) in the community. They are employed by the health system and 
are the primary contact between the community and health system. 
Community volunteers. They are community members, chosen by their 
community, who offer their services as volunteers.  They are concerned with the 
welfare of the people in relation to improving health and preventing illness. 
Table 1: Personnel involved in MDA at district level in Kenya
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A community health extension worker 
(CHEW) in Kataboi dispensary, turkana 
County, gives azithromycin to a child 
during mass drug administration. KENyA
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4. training community health 
extension workers and 
community volunteers
Training CHEWs and community volunteers 
before MDA ensures smooth implemen-
tation. There are three phases of training. 
The first two-day training session is for 
divisional coordinators and supervisors
from all over the district that will carry
out MDA. The second two-day training 
session is for CHEWs, who are team leaders 
at the distribution posts. Finally, there is
a one-day training session for community 
volunteers. 
Everyone is taught about trachoma and 
SAFE, the trachoma situation in the country 
and respective districts, the pharmacology 
of azithromycin (with emphasis on uses, 
doses and possible side effects), the 
mapping of the distribution area, dosing of 
azithromycin and the use of the height 
stick, writing patient details, and how to 
write the daily summary reports. The 
different duties of the divisional coordinators, 
supervisors, CHEWs and community volun-
teers are then clearly explained to each 
respective group.  
5. Mass treatment
The CHEWs are responsible for all activities 
at the treatment posts. These include identi-
fying the areas that have not been visited. In 
cases of side effects or adverse drug 
reactions, CHEWs give fi rst aid and notify the 
Ministry of Health immediately.
During the MDA, a CHEW is paired with 
two community volunteers. One volunteer 
measures the height of each person who will 
receive treatment to establish the appropriate 
dose, and th e second volunteer records the 
personal details and the dose the person will 
receive. The antibiotic (azithromycin) is 
administered by the CHEW according to 
height, and older people are also examined 
for trichiasis. At the end of each day the 
CHEW tabulates the number of people 
treated and the drugs used as well as any 
wastage, and sends the daily summary to
the supervisor. 
The supervisors and divisional coordi-
nators have broadly similar roles, just at 
different levels. They work together to ensure 
every team has enough azithromycin to 
ensure smooth distribution and that unused 
drugs are returned to a central store. 
Supervisors collate the reports submitted by 
teams and send them to the coordinator 
they report to. Coordinators collate all the 
supervisor reports and send them to the DHMT. 
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Clinical case study
A 19-year-old college student complains of poor vision. He states that he has long 
been nearsighted but that his glasses have recently required several changes, and 
even with his most recent correction, he is having difficulty. Examination reveals a 
best-corrected acuity of 20/40 with spectacle correction. The results of slit lamp 
biomicroscopy are shown.
What is the most likely diagnosis?
 Keratoconus  Pellucid marginal degeneration
 Terrien’s marginal degeneration  Keratoglobus
Keratoconus is the most likely diagnosis.
The patient’s history and corneal appearance 
on biomicroscopy are most consistent with 
keratoconus. Progressive myopia, multiple 
spectacle or contact lens changes, and a 
qualitatively unsatisfactory best-corrected 
acuity suggest early keratoconus. The presence 
of a distinct Fleischer ring representing iron 
deposition at the level of the basal epithelium 
is diagnostic of this disorder. 
      Pellucid marginal degeneration is a distinct 
disorder in the spectrum of noninfl ammatory 
ectasias of the cornea; however, it differs from 
keratoconus in that the thinnest area of the 
cornea is not at the apex of the cone, but 
rather in a crescentic distribution near the 
inferior limbus. The effect of this pathologic 
confi guration is that the patient presents with 
progressive and marked against-the-rule
astigmatism. 
      Generally, there is no circular iron 
deposition or apical reticular scarring as in 
keratoconus. Keratoglobus is a diffuse thinning 
of the ocular coats, including cornea and 
sclera. Patients with keratoglobus often have a 
markedly steepened cornea, a blue sclera, 
and a tendency for corneal rupture with 
trauma. There is also an association with 
collagen fragility syndromes. 
      Terrien’s marginal degeneration is an 
infl ammatory condition that includes 
peripheral vascularisation, intracorneal lipid 
deposition, and nonulcerative thinning and 
ectasia of the corneal periphery.
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A 35-year-old man presented at our 
eye clinic with a 2-day history of a red, 
sore and watery right eye. He had visited 
Cameroon 4 months prior to presentation.
Examination of the right eye revealed 
an injected conjunctiva and a coiled, 
mobile and translucent worm in the 
sub-conjunctival space (Figure 1). A 
diagnosis of loiasis was made on the 
basis of clinical examination, parasito-
logical analysis, a full blood count 
(which revealed eosinophilia) and a 
blood fi lm (which showed microfi laria).
Removal of the worm (Loa loa) was 
attempted using an aseptic technique 
and minimal illumination. A sub-
conjunctival injection of 2% lignocaine 
and 1:100,000 dilution of adrenaline 
was used to anaesthetise the eye and a 
2 cm horizontal conjunctival incision 
was made. Despite multiple attempts 
to grasp the worm with forceps, it could 
not be extracted due to its slippery 
exterior. Gentle cautery was applied to 
seal the space around the worm and 
facilitate removal. Topical antibiotic 
was then applied and the conjunctiva 
closed with 6/0 vicryl. Within a week, 
the patient’s ocular symptoms improved.
Loa loa is a fi larial nematode with a 
predilection for ocular tissues.  With 
increasing international travel it is 
important that ophthalmologists 
become familiar with the various ocular 
presentations of infectious diseases, 
which untreated can cause serious 
morbidity and mortality. 
Figure 1
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